What Senescence Experts Actually Think About Senolytics Right Now
Cellular senescence has become one of the most active frontiers in longevity science.
Senescent cells occupy a strange biological position. They stop dividing — which protects against cancer — but remain metabolically active and secrete a persistent stream of inflammatory molecules known as the SASP. In young tissue, the immune system clears them efficiently. With age, that clearance falters and senescent cells accumulate. The therapeutic logic of removing them selectively, or blunting their secretions, has driven an entire research field into existence over the past decade. Lifespan.io gathered a group of experts to take stock of where things actually stand.
The emerging consensus, as reflected in the roundup, is that the underlying biology is solid — but that the translation into clinical medicine is harder than early animal models suggested. One issue that kept surfacing: senescence is not a single, uniform state. Different cell types become senescent in different ways, their SASP profiles vary, and what works to clear senescent cells in one tissue context may be irrelevant or even counterproductive in another.
Clinical evidence: promising but uneven
The most studied senolytics — dasatinib combined with quercetin — have now completed several clinical trials in conditions including chronic kidney disease, idiopathic pulmonary fibrosis, and diabetic kidney disease. Some results look encouraging; others have been disappointing or inconclusive. Experts in the roundup highlighted that dosing timing appears to be critical: intermittent ‘burst’ dosing seems to outperform chronic administration in some models, but the optimal regimen in humans is still unknown.
Measurement remains a deep problem. There is no widely validated biomarker for senescent cell burden in humans — no blood test that reliably indicates how many senescent cells are present, where they are concentrated, or whether a treatment has reduced them. Without that, clinical trials are flying somewhat blind, relying on indirect functional outcomes rather than direct measures of what the therapy is supposed to do.
When the market moves faster than the science
Outside academia, the commercial market for senolytic supplements is expanding rapidly. Quercetin and fisetin are widely available without a prescription, marketed with implicit or explicit anti-aging claims, despite minimal human evidence for senolytic efficacy at typical supplementation doses. Several experts expressed concern about this gap — not only because consumers may be spending money on ineffective products, but because poorly documented self-experimentation could complicate the interpretation of future trials.
The field is at an inflection point. The fundamental biology is compelling enough that major pharmaceutical companies and well-funded startups are now running serious clinical programs. Whether senolytics will eventually be proven to meaningfully extend healthy human lifespan, or turn out to be effective only in specific disease contexts, remains genuinely unresolved.